1 October 2025 in Diabetes, Metabolic Syndrome and Obesity
Objective: To explore the relationship between controlled attenuation parameters (CAP) of the liver and the risk of type 2 diabetes mellitus (T2DM), and to determine the optimal cutoff value of CAP for predicting T2DM. Methods: This study employed a cross-sectional study design, enrolling 7035 participants. CAP values were measured using hepatic transient elastography, and participants were categorized into low (≤ 231 dB/m), middle (232~269 dB/m), and high (≥ 270 dB/m) groups. Multivariate logistic regression analysis was used to assess the association between CAP and T2DM, and the optimal cutoff value was determined using receiver operating characteristic (ROC) curves. Results: After adjusting for potential confounders, participants in the high-CAP group had a significantly greater risk of developing T2DM than did those in the low-CAP group (OR=1.545; 95% CI=1.263– 1.890; p< 0.001). Stratified analyses revealed that compared with a low CAP, a 1.0-increased CAP was associated with a 0.852-fold increased T2DM risk in people aged < 55 years (OR=1.852; 95% CI=1.405– 2.441; p< 0.001) and a 0.6-fold increased T2DM risk in overweight patients (BMI≥ 24 kg/m2) (OR=1.600; 95% CI=1.127– 2.271; p=0.009). ROC analysis revealed an optimal CAP cutoff value of 246.5 dB/m for T2DM prediction, with an area under the curve of 0.569 (specificity=48.2%, sensitivity=64.2%). Conclusion: CAP levels are associated with a dose-response relationship with the risk of T2DM, particularly in younger and overweight populations. Although CAP has limited predictive value on its own, it can be used as an auxiliary indicator for T2DM risk screening.
1 December 2024 in Diabetes, Metabolic Syndrome and Obesity
The aim of the present study was to investigate how thyroid hormone levels are related to controlled attenuation parameters (CAP), which may provide insights for understanding the role of these factors in hepatic steatosis. A total of 3461 participants who underwent CAP diagnosis between 2018 and 2023 were included. The associations between thyroid hormone levels and CAP were evaluated through multiple linear regression, restricted cubic splines (RCS) and threshold effect analyses. Multiple linear regression analysis revealed an inverse relationship between free thyroxine (FT4) and CAP, with a coefficient of −0.855 and a confidence interval of −1.297 to −0.412. The negative connection in a subset examination persisted in males [−0.729 (−1.295, −0.162)] and females [−1.234 (−1.996, −0.473)]. A strong correlation was found between free 3,5,3′-triiodothyronine (FT3) and CAP, with values of 2.182 (1.154, 3.211). Further analysis was conducted on both male [1.626 (0.188, 3.065)] and female [2.835 (1.137, 4.533)] subgroups. In the severe liver steatosis group, there was a significant negative correlation between FT3 and CAP based on the subgroup analysis stratified by the level of liver steatosis [−3.804 (−6.711, −0.898)]. The RCS analysis showed a nonlinear association between FT4 and CAP, with a turning point at 11.14 pmol/L. There was a significant linear and nonlinear relationship between FT4, FT3 and CAP. Thyroid hormones could have a significant impact on liver steatosis, offering fresh perspectives on how to prevent and treat this condition.